[go: up one dir, main page]

KR870006008A - 신규의 벤즈아미드와 그것의 제법 및 제약학적 조성물 - Google Patents

신규의 벤즈아미드와 그것의 제법 및 제약학적 조성물 Download PDF

Info

Publication number
KR870006008A
KR870006008A KR860010868A KR860010868A KR870006008A KR 870006008 A KR870006008 A KR 870006008A KR 860010868 A KR860010868 A KR 860010868A KR 860010868 A KR860010868 A KR 860010868A KR 870006008 A KR870006008 A KR 870006008A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
amino
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR860010868A
Other languages
English (en)
Other versions
KR930004653B1 (ko
Inventor
아체르 잭끄스
클라우드 모니에 쟝
폴 스케미트 쟝
캬아르덱스-뤼떼로 레네
코스탈 브렌다
나이로르 로버트
Original Assignee
아랑갈로샤
쏘시에떼 데뛰드 시앙띠휘끄 에 앵뒤스트리엘 드 일-드-프랑스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아랑갈로샤, 쏘시에떼 데뛰드 시앙띠휘끄 에 앵뒤스트리엘 드 일-드-프랑스 filed Critical 아랑갈로샤
Publication of KR870006008A publication Critical patent/KR870006008A/ko
Application granted granted Critical
Publication of KR930004653B1 publication Critical patent/KR930004653B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

내용 없음

Description

신규의 벤즈아미드와 그것의 제법 및 제약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (31)

  1. 구조식 (1)의 신규 치환된 벤즈아미드와 광학 이성체 및 그것의 생리학적으로 허용 가능한 부가염.
    식 중, A는 알킬, 알케닐 또는 디에틸아미노에틸 그룹 또는
    R7은 수소원자 또는 알킬, 알케닐, 아릴, 아랄킬, 사이크롤알킬, 사이클로알킬알킬, 사이클로알케닐, 또는 사이클로알케닐알킬그룹, R1및 R2는 수소원자 또는 알킬 또는 알케닐 그룹, R,R4,R5및 R6은 수소원자 또는 알킬 그룹, X은 염소 또는 브롬같은 할로겐원자, Y는 수소원자 또는 염소 또는 브롬같은 할로겐원자, Z는 NH 그룹 또는 산소 또는 황원자이고 알킬 및 알케닐(환식 또는 지방족) 잔사는 C6까지 포함할 수 있다.
  2. 제1항에 있어서, 다음 구조의 화합물
    [식 중, X,Y,Z,R2,R3,R4,R5,R6은 제1항의 정의와 동일]
  3. 제1항 및 제2항에 있어서, N-[2-(디에틸아미노)에틸] 2-메톡시 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 5-클로로 벤즈아미드.
  4. 제1항 및 제2항에 있어서, N-[2-(디에틸아미노)에틸] 2-메톡시 4-[N-에틸, N-(1-H 4,5-디하이드로 2-이미다졸일)]아미노 5-클로로 벤즈아미드.
  5. 제1항 및 제2항에 있어서, N-[2-(디에틸아미노)에틸] 2-메톡시 3,5-디클로로 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 벤즈아미드.
  6. 제1항 및 제2항에 있어서, N-[2-(디에틸아미노)에틸] 2-메톡시 4-[(1-H 4,5-디하이드로 4-디메틸 2-이미다졸일)아미노] 5-클로로 벤즈아미드.
  7. 제1항 및 제2항에 있어서, N-[2-(디에틸아미노)에틸]2-메톡시 4-[(4,5-디하이드로, 1,3-디아졸 2-일)아미노] 5-클로로 벤즈아미드.
  8. 제1항 및 제2항에 있어서, N-[2-(디에틸아미노)에틸] 2-메톡시 4-[(4,5-디하이드로 2-옥시졸일)아미노] 5-클로로 벤즈아미드.
  9. 제1항에 있어서, 다음 구조의 화합물
    [식 중, X,Y,Z,R2,R3,R4,R5,R6,R7은 제1항의 정의와 동일]
  10. 제1항 및 제9항에 있어서, N-[(1-에틸 2-피롤리디닐)메틸] 2-메톡시 3,5-디브로모 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 벤즈아미드.
  11. 제1항 및 제9항에 있어서, N-[1-(1-사이클로헥세닐메틸 2-피롤리디닐)메틸] 2-메톡시 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 5-클로로 벤즈아미드.
  12. 제1항 및 제9항에 있어서, N-[(1-사이클로프로필메틸 2-피롤리디닐)메틸] 2-메톡시 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 5-클로로 벤즈아미드.
  13. 제1항 및 제9항에 있어서, N-(1-알릴 2-피롤리디닐메틸) 2-메톡시 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 5-클로로 벤즈아미드.
  14. 제1항 및 제9항에 있어서, N-(1-에틸 2-피롤리디닐메틸) 2-메톡시 4-[ 4,5-디하이드로 1,3 티아졸 2-일)아미노] 5-클로로 벤즈아미드.
  15. 제1항 및 제9항에 있어서, N-(1-사이클로프로필메틸 2-피롤리디닐메틸) 2-메톡시 4-[(4,5-디하이드로 2-옥사졸일)아미노] 5-클로로 벤즈아미드.
  16. 제1항에 있어서,N-(알릴) 2-메톡시 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 5-클로로 벤즈아미드.
  17. 구조식 (2)의 산 또는 그것의 한 반응성 유도체를
    [식 중, R1,R2,R3,R4,R5,R6,X,Y 및 Z는 제1항의 정의와 동일]
    구조식 (3)의 아민 또는 그것의 한 반응성 유도체로
    A-NH2(3)
    [식 중, A는 제1항의 정의와 동일] 처리하는 것으로 구성되는, 제1항에서 제16항까지의 화합물을 제조하는 방법.
  18. 제17항에 있어서, 다음 구조의 알킬 4-아미노 5 (또는 3,5)-할로 벤조에이트를
    [식 중, R은 알킬그룹;R1, X 및 Y는 제1항의 정의와 동일] 구조식 (4)의 알킬 4-이소티오시아네이로 벤조에이트로,
    다음에는 구조식 (5)의 4-(N′-아미노(또는 하이드록시)알킬)티오우레이도 유도체로,
    [식 중, B는 아미노 또는 하이드록시 그룹]
    다음에는 구조식 (6)의 4-[4,5-디하이드로 2-이미다졸일 (또는 2-티아졸일 또는 2-옥사졸일)아미노] 유도체로 전환시키고,
    구조식 (6) 화합물을 아미드화하여 상응하는 구조식 (1) 화합물을 얻거나, 또는 구조식 (6) 화합물을 아미드화하여 R4가 수소원자인 구조식 (1) 화합물을 얻고, 이것을 R2가 알킬 또는 알케닐 그룹인 구조식 (1) 화합물로 전환시키는 것으로 구성되는, 제1항에서 제16항까지의 구조식 (1) 화합물을 제조하는 방법.
  19. 제18항에 있어서, 구조식 (6)의 4[(4,5-디하이드로 2-이미다졸일 (또는 2-티아졸일 또는 2-옥사졸일)아미노] 유도체를
    구조식 (6a) 유도체로 전환시키고
    [식 중, R2는 알킬 또는 알케닐] 상응하는 구조식 (1) 화합물로 아미드화하는 것으로 구성되는, 제1항에서 제16항까지의 구조식 (1)화합물을 제조하는 방법.
  20. 제18항에 따르는 합성시 신규한 중간 생성물로서, 구조식 (4)의 알킬 4-이소티오시아네이토 벤조에이트.
  21. 제18항에 따르는 합성시 신규한 중간 생성물로서, 구조식 (5)의 알킬 4-(N′-아미노 (또는 하이드록시)알킬)티오우레이도 벤조에이트.
  22. 제18항에 따르는 합성시 신규한 중간 생성물로서, 구조식 (6)의 알킬 4-[4,5-디하이드로 2-티아졸일 (또는 2-옥사졸일)아미노]벤조에이트.
  23. 제19항에 따르는 합성시 신규한 중간 생성물로서, 구조식 (6a)의 알킬 4-[4,5-디하이드로 2-티아졸일 (또는 2-옥사질일)아미노]벤조에이트.
  24. 제17항 있어서, 다음 구조의 알킬 4-아미노 5(또는 3,5)-할로 벤조에이트를
    [식 중, R는 알킬 그룹, R1, X, 및 Y는 제1항의 정의와 동일] 구조식 (7)의 알킬 4-포밀아미노 벤조에이트로,
    다음에는 구조식 (8)의 알킬 4-디클로로포밀이미노 벤조에이트로,
    다음에는 Z가 NH 그룹인 (6)의 알킬 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 벤조에이트로 전환시키고, 구조식 (6) 화합물을 아미드화하여 상응하는 구조식 (1) 화합물을 얻거나 또는 구조식 (6) 화합물을 아미드화하여 R2가 수소원자인 구조식 (1) 화합물을 얻고, 그것을 R2가 알킬 또는 알케닐 그룹인 구조식 (1) 화합물로 전환시키는 것으로 구성되는, Z가 NH 그룹인 구조식 (1) 화합물을 제조하는방법.
  25. 제24항에 있어서, 구조식 (6) 화합물을 Z가 NH 그룹으로 R2가 알킬 또는 알케닐 그룹인 구조식 (6a) 유도체로 전환하고, 구조식 (6a) 화합물을 아미드화하여 구조식 (1) 화합물을 제조하는 방법.
  26. 제24항에 따르는 합성시 신규한 중간 생성물로서, 구조식 (7)의 알킬 4-포밀아미노 벤조에이트.
  27. 제24항에 따르는 합성시 신규한 중간 생성물로서, 구조식 (8)의 알킬 4-디클로로포밀이미노 벤조에이트.
  28. 제18항, 제19항, 제24항 및 제25항에 따르는 합성시 신규한 중간 생성물로서, Z가 NH 그룹인 구조식 (6)의 알킬 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 벤조에이트.
  29. 제19항 및 제25항에 따르는 합성시 신규한 중간 생성물로서, Z가 NH 그룹인 구조식 (6a)의 알킬 4-[(1-H 4,5-디하이드로 2-이미다졸일)아미노] 벤조에이트.
  30. 신규의 약제로서 제1항에서 제16항까지의 화합물.
  31. 활성 원리에 따라 최소한 하나의 제1항에서 제16항까지의 화합물과 제약학적으로 허용 가능한 부형제를 포함하는 것을 특징으로 하는 제약학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860010868A 1985-12-09 1986-12-18 신규의 벤즈아미드 및 그것의 제법 Expired - Fee Related KR930004653B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8518829A FR2592042B1 (fr) 1985-12-19 1985-12-19 Nouveaux ortho-anisamides, leur procede d'obtention, et leurs applications therapeutiques
FR8518829 1985-12-19

Publications (2)

Publication Number Publication Date
KR870006008A true KR870006008A (ko) 1987-07-08
KR930004653B1 KR930004653B1 (ko) 1993-06-02

Family

ID=9325965

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860010868A Expired - Fee Related KR930004653B1 (ko) 1985-12-09 1986-12-18 신규의 벤즈아미드 및 그것의 제법

Country Status (37)

Country Link
US (2) US4835172A (ko)
EP (1) EP0236646B1 (ko)
JP (1) JPS62246553A (ko)
KR (1) KR930004653B1 (ko)
CN (1) CN1018454B (ko)
AR (1) AR242193A1 (ko)
AT (1) ATE57376T1 (ko)
AU (1) AU586057B2 (ko)
CA (2) CA1298301C (ko)
CH (1) CH671396A5 (ko)
CS (1) CS274285B2 (ko)
DD (1) DD260495A5 (ko)
DE (2) DE3674916D1 (ko)
DK (1) DK612886A (ko)
ES (1) ES2036178T3 (ko)
FI (1) FI865190A7 (ko)
FR (1) FR2592042B1 (ko)
GB (1) GB2184723B (ko)
GR (1) GR3002524T3 (ko)
HU (1) HU196794B (ko)
IE (1) IE59212B1 (ko)
IL (1) IL81010A (ko)
IN (1) IN163130B (ko)
IS (1) IS1448B6 (ko)
MA (1) MA20835A1 (ko)
NO (1) NO168176C (ko)
NZ (1) NZ218675A (ko)
OA (1) OA08564A (ko)
PH (2) PH24365A (ko)
PL (1) PL148408B1 (ko)
PT (1) PT83982B (ko)
SU (1) SU1496632A3 (ko)
TN (1) TNSN86165A1 (ko)
YU (1) YU44796B (ko)
ZA (1) ZA869560B (ko)
ZM (1) ZM10686A1 (ko)
ZW (1) ZW24886A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295350B1 (fr) * 1987-06-17 1992-11-11 Laboratoires DELAGRANGE Application du N-[2-(diethylamino)ethyl]2-methoxy 4-[(1-H 4,5-dihydro-2-imidazolyl) amino]5-chloro benzamide comme anxiolytique et anti-psychotique
FR2640139A1 (fr) * 1988-12-14 1990-06-15 Delagrange Laboratoires Application de benzamides substitues comme gastromoteurs
FR2640507A1 (fr) * 1988-12-20 1990-06-22 Delagrange Laboratoires Application de benzamides substitues comme anxiolytiques et anti-psychotiques
FR2645742A1 (fr) * 1989-04-12 1990-10-19 Delagrange Laboratoires Application de derives de 2-methoxy 4-(4,5-dihydro 2-imidazolyl (ou 2-oxazolyl) amino) 5-chloro benzamide dans le traitement des troubles de la fonction cognitive
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US20050140688A1 (en) * 2003-12-29 2005-06-30 Kim Pallister Method and mechanism for programmable filtering of texture map data in 3D graphics subsystems

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342826A (en) * 1964-01-13 1967-09-19 Ile De France Heterocyclic aminoalkyl benzamides
FR1539104A (fr) * 1967-07-31 1968-09-13 Ile De France Nouveaux benzamides et leur procédé de préparation
US3682968A (en) * 1969-06-25 1972-08-08 Merck & Co Inc Anti-inflammatory salicylic acid derivatives
DE1963193A1 (de) * 1969-12-17 1971-06-24 Bayer Ag N-substituierte 2-Arylimino-oxazolidine,Verfahren zu ihrer Herstellung und ihre Verwendung als Ektoparasiticide
FR2432513A1 (fr) * 1977-10-24 1980-02-29 Merieux Inst Nouveaux derives de la thiazoline et leur application comme medicaments
DE2905883A1 (de) * 1979-02-16 1980-08-28 Boehringer Sohn Ingelheim Radioimmuntest fuer clonidin
CA1201066A (en) * 1981-11-20 1986-02-25 Alcon Laboratories, Inc. N-¬3,5-dichloro-4-(2-imidazolidinylideneamino)- phenyl|-acetamide solutions for lowering intraocular pressure
US4461904A (en) * 1981-11-20 1984-07-24 Alcon Laboratories, Inc. 2-(Trisubstituted phenylimino)-imidazolines
DE3514351A1 (de) * 1985-04-20 1986-11-06 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte 2-(n-alkinyl-n-phenyl)amino)-imidazolinderivate, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
JPS6341471A (ja) * 1986-08-08 1988-02-22 Nippon Soda Co Ltd オキサ（チア）ゾリジン誘導体、その製造法及び殺ダニ剤
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents

Also Published As

Publication number Publication date
FI865190A0 (fi) 1986-12-18
US4835172A (en) 1989-05-30
GB2184723A (en) 1987-07-01
ATE57376T1 (de) 1990-10-15
GB8630143D0 (en) 1987-01-28
JPS62246553A (ja) 1987-10-27
GR3002524T3 (en) 1993-01-25
DE3674916D1 (de) 1990-11-15
CS960386A2 (en) 1990-09-12
KR930004653B1 (ko) 1993-06-02
AR242193A1 (es) 1993-03-31
GB2184723B (en) 1989-12-28
CN86108972A (zh) 1987-11-18
PT83982A (en) 1987-01-01
CA1298301C (fr) 1992-03-31
FR2592042A1 (fr) 1987-06-26
FR2592042B1 (fr) 1988-03-25
ZM10686A1 (en) 1987-11-27
IE863270L (en) 1987-06-19
NZ218675A (en) 1990-06-26
PH24365A (en) 1990-06-13
ZA869560B (en) 1987-11-25
CH671396A5 (ko) 1989-08-31
IS3178A7 (is) 1987-06-20
IS1448B6 (is) 1991-01-16
YU44796B (en) 1991-02-28
ZW24886A1 (en) 1987-05-13
AU6668786A (en) 1987-06-25
CA1299579C (fr) 1992-04-28
IE59212B1 (en) 1994-01-26
NO168176B (no) 1991-10-14
NO168176C (no) 1992-01-22
IL81010A (en) 1991-06-30
DK612886D0 (da) 1986-12-18
ES2036178T3 (es) 1993-05-16
OA08564A (fr) 1988-09-30
MA20835A1 (fr) 1987-07-01
AU586057B2 (en) 1989-06-29
NO865148L (no) 1987-06-22
EP0236646B1 (fr) 1990-10-10
HUT43844A (en) 1987-12-28
CS274285B2 (en) 1991-04-11
HU196794B (en) 1989-01-30
FI865190A7 (fi) 1987-06-20
US4914117A (en) 1990-04-03
DD260495A5 (de) 1988-09-28
DE3643103A1 (de) 1987-06-25
PL148408B1 (en) 1989-10-31
YU217986A (en) 1987-12-31
DK612886A (da) 1987-06-20
PH24469A (en) 1990-07-18
PT83982B (pt) 1989-01-17
SU1496632A3 (ru) 1989-07-23
PL263078A1 (en) 1988-04-14
NO865148D0 (no) 1986-12-18
IL81010A0 (en) 1987-03-31
EP0236646A1 (fr) 1987-09-16
CN1018454B (zh) 1992-09-30
IN163130B (ko) 1988-08-13
TNSN86165A1 (fr) 1990-01-01

Similar Documents

Publication Publication Date Title
KR940000447A (ko) 티아졸의 분지쇄 알킬아미노유도체, 그의 제조방법 및 그를 함유하는 약제학적 조성물
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
NO20001100L (no) IL-8 reseptorantagonister
RU93048539A (ru) Производные оксазолидина, обладающие противодиабетическими свойствами и действием против ожирения, их получение и терапевтическое применение
ATE40368T1 (de) Xanthin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
RU2006105101A (ru) Арилокси и арилалкиленокси замещенные имидазохинолины
KR960034194A (ko) N-(3-벤조푸라닐)우레아 유도체
RU97119064A (ru) Применение альфа(il)-агонистов для лечения недержания мочи
KR870006008A (ko) 신규의 벤즈아미드와 그것의 제법 및 제약학적 조성물
KR900004658A (ko) 이치환 벤질아민, 그의 제조방법, 약제로서의 그의 용도 및 그의 합성 약제
KR870007160A (ko) 신규의 디하이드로벤조푸란-및 크로만-카복스아미드 유도체, 그것의 제조 방법 및 신경이완제로서의 사용법
NO152047C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksom 5-(paradeuterofenyl)-5-fenylhydantoin
PT90740A (pt) Processo para a preparacao de oligopeptideos com aminoacidos analogos de prolina ciclicos, e de composicoes farmaceuticas que os contem
EA199900648A1 (ru) Замещенные производные (1,3-бис(циклогексилметил)-1,2,3,6-тетрагидро-2,6-диоксо-9н-пурин-8-ил) фенила, их получение и их применение при лечении воспалительных состояний и иммунных расстройств
PT92558A (pt) Processo para a preparacao de derivados de aminoacidos inibidores de enzimas e de composicoes farmaceuticas que os contem
HU895336D0 (en) Process for producing beta-delta-phenylthioxylosides and pharmaceutical compositions comprising such compounds as active ingredient
WO2000054808A1 (fr) Agoniste du recepteur ep4 de la prostaglandine et traitement correspondant
PT86656A (pt) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amino-6h-1,3,4-thadiazine verfahren zu ihrer herstellung die sie enthaltenden arzneimittel und ihre verwendung
RU2003130070A (ru) Производные бигуанида
RU2227750C2 (ru) Композиция для предотвращения и лечения вич-1 инфекции, ее применение
KR890014484A (ko) 질병으로 부터 식물을 보호하기 위한 조성물
PT92388A (pt) Processo para a preparacao de derivados de aminodiol inibidores de renina e de composicoes farmaceuticas que os contem
EP0384843A3 (fr) Dérivés de la 1-arylsulfonyl 2-pipéridinone, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant
KR900701761A (ko) 중추 신경계 활성을 갖는 아세틸렌계 이미다졸
RU98107807A (ru) Новые гетероциклические соединения

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19960603

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19960603